4D Molecular Therapeutics, Inc. 4

David Kirn, CEO of 4D Molecular Therapeutics (FDMT), exercised 50,000 stock options at $4.14 and sold 69,076 common shares for about $1.1 million on August 19, 2026 under a 10b5-1 plan.

On August 19, 2026, David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc., exercised 50,000 stock options at an exercise price of $4.14 per share, acquiring 50,000 shares of common stock, and on the same day sold an aggregate 69,076 shares of common stock in two market transactions under a Rule 10b5-1 trading plan at weighted average prices of $15.3566 and $16.4173 per share. The option exercise, which related to a grant vesting monthly from March 6, 2025 through March 6, 2029, resulted in a gross implied value of approximately $207,000 based on the stated $4.14 exercise price, while the sales generated total proceeds of roughly $1.09 million. After these transactions, Kirn directly owned 825,819 shares of common stock, which, using the sale prices as a proxy for market value, represent an equity stake worth on the order of $12.7–$13.6 million, indicating that despite the pre-planned liquidity sales, he maintains a substantial continuing ownership interest in the company.

Filing Facts

CIK

1650648

Ticker

FDMT

Form

4

Source Type

fda

Accession

0001193125-26-361096

Alert Tier

7